• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chemocentryx Inc (NQ: CCXI )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 51.97 (10)
    Ask (Size) 52.00 (55)
    Prev. Close 51.99
    Today's Range N/A - N/A
    52wk Range N/A - N/A
    Shares Outstanding 71,355,872
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
    Via Benzinga
    How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
    Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
    Via Benzinga

    Performance

    More News

    Read More
    ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
    From ChemoCentryx, Inc.
    Via GlobeNewswire
    Biotech Stocks Well-Positioned For The Fourth Quarter
    Via Talk Markets
    ChemoCentryx: Q2 Earnings Insights
    Via Benzinga
    ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From ChemoCentryx, Inc.
    Via GlobeNewswire
    These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
    Via Talk Markets
    Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
    Via Investor's Business Daily
    Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
    Via Investor's Business Daily
    INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
    From Scott+Scott Attorneys at Law LLP
    Via Business Wire
    7 Dow Stocks With Superior Fundamentals
    Via InvestorPlace
    Healthcare Sector Still Looks Good But Lacks Momentum
    Via Talk Markets
    ChemoCentryx's Return On Capital Employed Insights
    Via Benzinga
    INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
    From Scott+Scott Attorneys at Law LLP
    Via Business Wire
    10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
    Via Investor's Business Daily
    Whither Small Caps After Fed’s Tough Talk?
    Via Talk Markets
    Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
    Via Investor's Business Daily
    Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
    Via Talk Markets
    Why Jim Cramer Says This Financial Stock Is 'Terrific'
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
    Via Benzinga
    Earnings Preview: ChemoCentryx
    Via Benzinga
    Small Cap Biotechs Perk Up On Dealmaking
    Via Talk Markets
    Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
    Via Investor's Business Daily
    Where ChemoCentryx Stands With Analysts
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.